Service Communautaire d'Information sur la Recherche et le Développement - CORDIS

FP5

ANTI TUMOR ANGIOGENESI Résumé de rapport

Project ID: QLK3-CT-2002-02059
Financé au titre de: FP5-LIFE QUALITY
Pays: Germany

Promoter for endothelial-specific expression in gene therapy vectors

The size of a VEGFR-2 promoter/enhancer construct was cut down from 2.3kbp to 510bp without loosing its endothelial specificity and transcriptional strength. This was shown by lacZ reporter analysis of both transient embryonic expression as well as analysis of transgenic mice, in which experimental tumours were analyzed. A patent was applied for and granted for this fragment and its use in gene therapy vectors for specific expression of therapeutic genes in tumor endothelium.

Publication: Licht AH, Raab S, Hofmann U, Breier G. Endothelium-specific Cre recombinase activity in flk-1-Cre transgenic mice. Dev Dyn 2004;229:312-8.
Patent: Breier G, Kappel A, Risau W, Rönicke V: Regulatory sequences capable of conferring expression of a heterologous DNA sequence in endothelial cells in vivo and uses thereof (European Patent Nr. 1007714, published 14.12.2005 Bulletin 2005/50, International Publication Number WO 1998/055638).

Informations connexes

Contact

Georg BREIER, (Department Head)
Tél.: +49-351-4585278
Fax: +49-351-4584328
E-mail